Summary
The provided AI claims largely concern metoprolol succinate (including ER formulation, hypertension/angina/heart failure, brand/patent information, and generic availability), but the FDA label excerpts provided are for metoprolol tartrate injection for acute myocardial infarction. These claims cannot be considered label-concordant for the submitted drug label, and multiple items appear unsupported or misaligned with the provided indication/mechanism/formulation.
Category Scores
Accurate Statements
Metoprolol succinate is formulated for extended-release.
Unsupported by the provided label excerpts (which are for metoprolol tartrate injection, not an ER succinate formulation).
Unsupported Statements
Metoprolol succinate 50 mg is available under the brand name Extended Release Metoprolol Succinate.
No brand-name or strength-specific availability information is present in the provided label excerpts.
Metoprolol succinate is used to treat high blood pressure.
Provided label excerpts describe metoprolol tartrate injection indicated to reduce cardiovascular mortality in definite or suspected acute myocardial infarction with oral metoprolol maintenance therapy; hypertension indication is not supported.
Metoprolol succinate is used to treat chest pain (angina).
Angina indication is not supported by the provided label excerpts.
Metoprolol succinate is used to treat heart failure.
Heart failure is mentioned only in warnings/adverse reactions context for metoprolol tartrate injection; the AI claim presents it as an indication for metoprolol succinate, which is not supported.
Metoprolol succinate is a beta-blocker prescribed to manage hypertension.
Hypertension management indication is not supported by the provided label excerpts.
Metoprolol succinate reduces the frequency of angina attacks.
No such efficacy statement is present in the provided label excerpts.
Metoprolol succinate improves survival rates in patients who have had a heart attack.
The provided label excerpts include a mortality reduction in myocardial infarction for metoprolol tartrate injection, but the AI claim is specifically about metoprolol succinate and survival; this is not supported for succinate based on the provided excerpts.
Metoprolol succinate is used in some cases to treat heart failure.
Not supported as an indication in the provided label excerpts.
Metoprolol succinate works by blocking the effects of certain stress hormones, like adrenaline.
The provided label mechanism states beta1-selective adrenergic receptor blocking; 'adrenaline' wording and broader description are not supported by the provided excerpts.
Metoprolol succinate slows the heart rate.
Heart rate reduction is supported for metoprolol tartrate injection (pharmacodynamics), but not for metoprolol succinate specifically based on provided excerpts.
Metoprolol succinate reduces the force with which the heart pumps blood.
Cardiac output reduction is stated for metoprolol tartrate injection; 'force with which the heart pumps blood' is not an exact supported claim for succinate.
The succinate formulation indicates an extended-release version.
No succinate/ER naming rule is stated in the provided label excerpts.
Extended-release metoprolol succinate releases medication slowly over time.
No ER/succinate formulation description is in the provided label excerpts.
The patent status for metoprolol succinate can vary depending on specific formulations and geographical regions.
Patent status information is not addressed in the provided label excerpts.
Information on patent expiry dates for specific drugs, including metoprolol succinate, can be found on DrugPatentWatch.com.
External patent database guidance is not present in the provided label excerpts.
Generic versions of metoprolol succinate are available.
Availability of generics is not addressed in the provided label excerpts.
Once patents expire, other pharmaceutical companies can manufacture and market generic equivalents of metoprolol succinate.
Patent/legal process is not addressed in the provided label excerpts.
Generic metoprolol succinate are typically bioequivalent to the brand-name drug.
Bioequivalence expectations for generics are not addressed in the provided label excerpts.
Bioequivalent generic metoprolol succinate perform the same way in the body as the brand-name drug.
Such general statements are not addressed in the provided label excerpts.
Common side effects of metoprolol succinate can include fatigue.
Tiredness is reported in the provided label excerpts, but the AI claim is not supported specifically for metoprolol succinate based on the provided excerpts.
Common side effects of metoprolol succinate can include dizziness.
Dizziness is reported in the provided label excerpts, but the AI claim is not supported specifically for metoprolol succinate based on the provided excerpts.
Common side effects of metoprolol succinate can include slow heart rate.
Bradycardia is reported in the label for metoprolol tartrate injection; not supported specifically for metoprolol succinate.
Common side effects of metoprolol succinate can include shortness of breath.
Dyspnea has been reported in the label; not supported specifically for metoprolol succinate.
Common side effects of metoprolol succinate can include cold extremities.
Cold extremities are reported post-marketing for metoprolol (tartrate injection context), but not supported as a common side effect specifically for metoprolol succinate in the provided excerpts.
Less common but more serious side effects of metoprolol succinate may occur and may require immediate medical attention.
The label excerpts do not categorize 'less common'/'more serious' or advise 'immediate medical attention' in that general phrasing.
Metoprolol succinate is formulated for extended-release.
ER formulation for succinate is not supported by the provided label excerpts.
Extended-release metoprolol succinate provides a consistent level of the drug in the body over 24 hours.
No 24-hour exposure/consistency statement is in the provided label excerpts.
Metoprolol tartrate is an immediate-release formulation.
The provided label excerpts do not define metoprolol tartrate as immediate-release vs extended-release.
Metoprolol tartrate is absorbed and acts more quickly than extended-release metoprolol succinate.
The provided label excerpts do not compare absorption/acting speed versus extended-release succinate.
Metoprolol tartrate typically requires multiple doses per day.
The provided label excerpts describe a specific acute MI regimen (three IV boluses) and transition to oral metoprolol, but do not state 'multiple doses per day' as a general dosing requirement.
Besides Extended Release Metoprolol Succinate, other brand names may be associated with metoprolol succinate depending on the manufacturer and market.
No brand-name mapping information is in the provided label excerpts.
Generic versions of metoprolol succinate are widely available under their chemical name.
Availability and naming practices for generics are not addressed in the provided label excerpts.
Contradictions
Low
AI Statement
Metoprolol succinate is used to treat high blood pressure.
Label Reference
Label Indications and Usage excerpt provided is for metoprolol tartrate injection to reduce cardiovascular mortality in definite or suspected acute myocardial infarction when used with oral metoprolol maintenance therapy; hypertension indication is not stated.
Important Omissions
Any label-supported indication/dosing/safety for metoprolol tartrate injection (e.g., acute MI IV bolus regimen, transition to oral therapy, contraindications such as bradycardia/heart block/low BP, and bradycardia monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The claims primarily concern metoprolol succinate indications, formulation, and general side effects/availability, but the supplied FDA label excerpts correspond to metoprolol tartrate injection for acute myocardial infarction with specific administration and contraindications. Mismatch with the provided label increases risk of using incorrect product/indication information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large mismatch between the drug/formulation in the AI claims (metoprolol succinate ER) and the provided FDA label excerpts (metoprolol tartrate injection for acute myocardial infarction). Many claims are unsupported by the excerpted label sections.
Suggested Improvement
Limit claims to what is explicitly supported by the provided label excerpts for metoprolol tartrate injection (acute MI indication, IV dosing regimen, monitoring, contraindications, listed warnings/precautions, adverse reactions, and interactions). Remove or clearly separate non-label information (brand/patent/generic availability) unless supported by the label excerpts.